Wei Hu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 25

Top Topics

Metastatic Colorectal Cancer

Signaling Pathway

Top Venues

American journal of cardiovascular drugs : drugs, devices, and other interventions

Clinical pharmacokinetics

Expert opinion on investigational drugs

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert opinion on investigational drugs 33 (5) (2024)
Liang Ni, Zhihai Cao, Jiakang Jiang, Wei Zhang, Wei Hu, Qian Zhang, Chaozhuang Shen, Xijing Chen, Liang Zheng
Evaluating Drug Interactions between Ritonavir and Opioid Analgesics: Implications from Physiologically Based Pharmacokinetic Simulation. Pharmaceuticals (Basel, Switzerland) 17 (5) (2024)
Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert opinion on investigational drugs (2024)
Feng Yao, Chenguang Wang, Jie Ding, Qian Zhang, Liang Zheng, Qin Zhang, Tianshu Yang, Xunmin Zhang, Yong Shan, Sheng Hou, Hao Wang, Renpeng Zhou, Wei Hu
A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx ® in Healthy Chinese Male Subjects. Drug design, development and therapy 18 (2024)
Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects. Expert opinion on investigational drugs 33 (5) (2024)
Cheng Sun, Hao Liu, Ziwei Ouyang, Jie Ding, Qin Zhang, Hongjie Ma, Dandan Xu, Qian Zhang, Renpeng Zhou, Mingming Yang, Wei Hu
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind phase I study in healthy subjects. Expert opinion on investigational drugs (2024)
Yuru Fan, Xuan Zhang, Qin Zhang, Liang Zheng, Renpeng Zhou, Cheng Sun, Xihan Wang, Ke Song, Zhusheng He, Honghui Wang, Qian Zhang, Wei Hu
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical pharmacokinetics (2024)
Liang Ni, Zhihai Cao, Jiakang Jiang, Wei Zhang, Wei Hu, Qian Zhang, Chaozhuang Shen, Xijing Chen, Liang Zheng
Evaluating Drug Interactions between Ritonavir and Opioid Analgesics: Implications from Physiologically Based Pharmacokinetic Simulation. Pharmaceuticals (Basel, Switzerland) 17 (5) (2024)
Yuru Fan, Xuan Zhang, Qin Zhang, Liang Zheng, Renpeng Zhou, Cheng Sun, Xihan Wang, Ke Song, Zhusheng He, Honghui Wang, Qian Zhang, Wei Hu
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical pharmacokinetics 63 (3) (2024)
Yuru Fan, Xuan Zhang, Qin Zhang, Liang Zheng, Renpeng Zhou, Cheng Sun, Xihan Wang, Ke Song, Zhusheng He, Honghui Wang, Qian Zhang, Wei Hu
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical pharmacokinetics 63 (3) (2024)
Yuru Fan, Xuan Zhang, Qin Zhang, Liang Zheng, Renpeng Zhou, Cheng Sun, Xihan Wang, Ke Song, Zhusheng He, Honghui Wang, Qian Zhang, Wei Hu
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. Clinical pharmacokinetics 63 (3) (2024)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Liang Ni, Liang Zheng, Yueyue Liu, Wenwen Xu, Yingjie Zhao, Ling Wang, Qian Zhang, Wei Hu, Xijing Chen
Physiologically Based Pharmacokinetic Modeling to Simulate CYP3A4-Mediated Drug-Drug Interactions for Pyrotinib. Advances in therapy (2023)
Huiling Qin, Yan Tan, Lei Diao, Ai-Min Hui, Zhuli Wu, Yongchun Zhou, Juan Sun, Xiao Xiang, Jingjun Qiu, Wei Hu
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults. Drugs in R&D (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Jingying Wu, Liang Zheng, Qian Zhang, Qin Zhang, Huiling Qin, Renpeng Zhou, Zhaoxing Chu, Guangwei He, Ling Wang, Wei Hu
LC-MS/MS determination of HY072808, a novel candidate for treating atopic dermatitis, and its active metabolite: Application to a first-in-human pharmacokinetic study. Biomedical chromatography : BMC (2022)
Yang Yang, Jie Ding, Yong Chen, Ganggang Ma, Xin Wei, Ren-Peng Zhou, Wei Hu
Blockade of ASIC1a inhibits acid-induced rat articular chondrocyte senescence through regulation of autophagy. Human cell 35 (2) (2022)
Huiling Qin, Liang Zheng, Yuanyuan Fang, Yueyue Liu, Anding Liu, Jinlian Wu, Fengjia Zhu, Jing Chen, Yijun Fan, Wei Hu
Pharmacokinetics, safety and bioequivalence of two formulations of progesterone soft capsule in healthy Chinese postmenopausal females: Impacts of a high-fat meal. Basic & clinical pharmacology & toxicology (2021)
Qian Zhang, Zhiqiang Wang, Jingying Wu, Zhen Zhou, Renpeng Zhou, Wei Hu
Bioequivalence and Pharmacokinetic Evaluation of Two Oral Formulations of Regorafenib: An Open-Label, Randomised, Single-Dose, Two-Period, Two-Way Crossover Clinical Trial in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Drug design, development and therapy 15 (2021)
Tianyi Chen, Renpeng Zhou, Yong Chen, Wanjin Fu, Xin Wei, Ganggang Ma, Wei Hu, Chao Lu
Curcumin ameliorates IL-1β-induced apoptosis by activating autophagy and inhibiting the NF-κB signaling pathway in rat primary articular chondrocytes. Cell biology international 45 (5) (2021)
Qian Zhang, Renpeng Zhou, Jingjing Yang, Changlin Dou, Tianyi Gan, Fujia Liu, Baihui Hu, Deyong Song, Chao Lu, Wei Hu
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Clinical Trial to Assess Safety, Tolerability, and Pharmacokinetics of LY-CovMab, a Potent Human Neutralizing Antibody Against SARS-CoV-2. Infectious diseases and therapy (2021)
Yueyue Liu, Qian Zhang, Chao Lu, Wei Hu
Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults. Drug design, development and therapy 15 (2021)